IL6 and neoplasm: To determine if increased glycolysis and thus ECAR in the presence of stromal IL6 is mediated by increased glucose transporter activity, we measured glucose uptake (using fluorescent glucose analog 2-NBDG) by the tumor cells after blocking IL6 receptor (using anti IL6R antibody) and glucose transporter inhibitor STF31.